DUBLIN, Dec. 20, 2023 /PRNewswire/ — The “Global Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), End-user, and Region – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.
The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.
The monoclonal antibodies segment accounted for the largest share by application in 2022
In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.
The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028
The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world’s R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.
The report provides insights on the following:
Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market.
Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market.
Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kuhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.
Market Dynamics
Drivers
Rising Demand for Biopharmaceuticals
Growing Adoption Among CDMOs and CMOs
Advantages of Continuous Bioprocessing Over Batch/Fed-Batch Mode
Favorable Regulatory & Government Support for Innovative Technologies
Emergence of Integrated End-To-End Continuous Bioprocessing
Restraints
High Capital Investments to Limit Entry for Smaller Players
Stringent Regulatory Requirements
Opportunities
High Growth Potential of Emerging Economies
Pat-Enabled Optimization of Continuous Bioprocessing
Challenges
Integration into Existing Manufacturing Facilities
Operational Challenges
Key Topics Covered:
Executive Summary
Continuous Bioprocessing Market, by Product, 2023 vs. 2028 (USD Million)
Continuous Bioprocessing Market, by Scale of Operation, 2023 vs. 2028 (USD Million)
Continuous Bioprocessing Market, by Process, 2023 vs. 2028 (USD Million)
Continuous Bioprocessing Market, by Application, 2023 vs. 2028 (USD Million)
Continuous Bioprocessing Market, by End-user, 2023 vs. 2028 (USD Million)
Geographical Snapshot of Continuous Bioprocessing Market
Premium Insights
Continuous Bioprocessing Market Overview – Rising Demand for Biopharmaceuticals to Drive Market Growth During Forecast Period
North America: Continuous Bioprocessing Market, by Product – Chromatography Systems & Consumables Segment Accounted for Largest Market Share in 2022
Continuous Bioprocessing Market, by Application – Monoclonal Antibodies Segment to Dominate Market During Forecast Period
Continuous Bioprocessing Market: Geographic Growth Opportunities – China to Register Highest Growth Rate During Forecast Period
Companies Mentioned
3D Biotek
3M
Bbi-Biotech
Bionet
Cell Culture Company
Corning
Danaher Corporation
Entegris
Eppendorf SE
Esco Lifesciences Group
Fibercell Systems
Fujifilm Holdings
Getinge Ab
Kuhner AG
Meissner Filtration Products
Merck KGaA
Omnibrx Biotechnologies
Pierre Guerin
Repligen
Sartorius
Satake Multimix
Solida Biotech
Stobbe Group
Thermo Fisher Scientific
Zellwerk
For more information about this report visit https://www.researchandmarkets.com/r/b9bhz9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
